Results 191 to 200 of about 16,236 (205)

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Lancet Oncology, The, 2016
Massimo Cristofanilli, Nicholas Turner, Igor N Bondarenko   +2 more
exaly  

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

Cancer Discovery, 2018
Ben O'Leary, Yuan Liu, Fabrice Andre
exaly  

Chemosensory characteristics of regional Vidal icewines from China and Canada

Food Chemistry, 2018
Yue Ma, Ke Tang, Yan Xu
exaly  

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Lancet Oncology, The, 2015
Richard Finn, John Crown, Katalin Boer
exaly  

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Annals of Oncology, 2018
Hope S Rugo, Miguel Martin, Johannes Ettl   +2 more
exaly  

Characterization of the Key Aroma Compounds in Chinese Vidal Icewine by Gas Chromatography–Olfactometry, Quantitative Measurements, Aroma Recombination, and Omission Tests

Journal of Agricultural and Food Chemistry, 2017
Yue Ma, Ke Tang, Yan Xu
exaly  

“Do jeito, simples, como experimento contar”

Em Tese, 2021
exaly  

Have Faith in the PALOMA-1 trial

Nature Reviews Clinical Oncology, 2014
exaly  

Genetics and mapping of a new anthracnose resistance locus in Andean common bean Paloma

BMC Genomics, 2017
Maria Celeste Gonçalves-Vidigal, Thiago Alexandre Santana Gilio, Giseli Valentini   +2 more
exaly  

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Annals of Oncology, 2016
Nadia Harbeck, Nicholas Turner, Massimo Cristofanilli   +2 more
exaly